Healthcare and pharmaceutical giant Johnson & Johnson (J&J) recently issued a recall of approximately 12 million bottles of its popular pain reliever, Motrin, due to concerns that the Motrin IB pills may not dissolve and begin working as quickly as intended, resulting in delayed pain relief, as the pills approach their three-year expiration date.Â The recall only affects Motrin IB from retailers, and not those in the hands of consumers, since there is no safety risk. The recalled bottles of Motrin were sold in 24 or 30 count packages that were distributed in the United States, Puerto Rico, the Bahamas, Fiji, Belize, St. Lucia and Jamaica.Â There are 59 affected lot numbers, all of which are listed on the product’s Web site at http://www.motrin.com.Â The affected bottles of Motrin were manufactured between February 2009 and July 2011. J&Jâ€™s Prior Recalls J&J has been plagued by safety problems and efficacy concerns with respect to its products for the past several years.Â Since September 2009, J&J has recalled a number of prescription and over-the-counter medications, including children’s and adult Tylenol and Motrin, Benadryl, Zyrtec, Rolaids, Simply Sleep pills, Prezista (an HIV medication), Levaquin (an antibiotic) and Topamax (an epilepsy medication).Â The manufacturer has also recalled a number of its medical devices, including hip replacement systems, contact lenses and diabetes test strips. As we reported, earlier last year, J&J was ordered to pay $1.8 million to an 82-year-old man from Minnesota who claimed that he was injured by Levaquin, an antibiotic used to treat infections such as pneumonia and chronic bronchitis, as well as sinus, urinary tract, kidney, prostate and skin infections.Â Levaquin has been known to cause complications including tendon damage, Achilles tendon rupture, inflammation, Achilles tendonitis, and injury to the rotator cuff, biceps, hand and thumb that may require extensive surgery and could leave the patient incapacitated and facing large medical bills. J&Jâ€™s recalls cost the company $900 million in 2010 alone as a result of lost revenue from products pulled from store shelves, factory renovation costs, and legal expenses. Â J&Jâ€™s Consumer Healthcare factory in Fort Washington, Pa., has been closed since spring 2010 when serious health problems forced the company to undergo a comprehensive renovation and rebuilding of the facility. J&Jâ€™s safety and efficacy concerns have sparked the interest of the federal government as well.Â The U.S. Food and Drug Administration (FDA) and Congress are both investigating how the companyâ€™s[READ MORE…]
Pfizer has agreed to pay $14.5 million to settle a lawsuit alleging that it violated the False Claims Act by improperly marketing its prescription drugs Detrol and Detrol LA.Â The lawsuit was filed by whistleblowers on behalf of the United States under the False Claims Act, which allows individuals (known as relators) with knowledge of fraud against the federal government to sue on its behalf.Â The relators receive a portion of any funds received by the federal government as a result of the lawsuit. The lawsuit had claimed that Pfizer improperly marketed the drugs to men suffering from the signs and symptoms of benign prostate hyperplasia (BPH), which is commonly referred to as an enlarged prostate, despite the fact that Detrol treats detrusor muscle overactivity and does not have any therapeutic effect on males whose symptoms are caused by BPH.Â Detrol and Detrol LA are prescription drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of â€œover active bladder with symptoms of urge incontinence, urgency and frequency.â€ The settlement resolves the last of a group of 10 whistleblower suits filed against Pfizer since 2003. The other nine lawsuits were settled or dismissed in 2009 when Pfizer agreed to pay $2.3 billion to resolve civil and criminal claims regarding multiple drugs.Â Pursuant to that settlement, Pfizer paid $1 billion to resolve False Claims Act allegations that the company had illegally promoted four drugs â€“ Bextra, Geodon, Zyvox, and Lyrica â€“ and had caused false claims to be submitted to government health care programs for uses of the drugs that were not medically accepted and not covered by those programs.Â The settlement also resolved allegations that kickbacks were made to health care providers to induce them to prescribe the drugs. The Chicago unsafe pharmaceutical drug attorneys at Ankin Law Offices, LLC represent clients throughout Illinois and the United States. We have significant experience handling class action lawsuits regarding unsafe pharmaceuticals and are familiar with the complex legal issues that these kinds of lawsuits generally involve.Â Â Contact us at (800) 442-6546 for more information on the improper marketing of Detrol or unsafe pharmaceuticals. Howard Ankin of Ankin Law Office LLC (www.ankinlaw.com) handles workersâ€™ compensation and personal injury cases. Mr. Ankin can be reached at (312) 346-8780 and firstname.lastname@example.org. ANKIN LAW OFFICE LLC Chicago Workers Compensation | Chicago Personal Injury | Chicago Motor Vehicle Accidents Chicago Wrongful Death |[READ MORE…]
Subscribe to this blog’s feed
- Coping With Work-Related Head Injuries
Work-related head injuries can lead to physical, mental, and financial hardships for an employee. A ...
- How Safe is Your Child’s Daycare?
Thousands of children suffer injuries in daycare homes and facilities across the United States every...
- The Liability of “Good Samaritans” In Illinois
Good samaritans are defined as individuals who render aid and assistance to individuals in the midst...
ankin law office llc
162 West Grand Avenue
Chicago, Illinois 60654
Toll Free: 800-442-6546